Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00623766 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
A Phase 2 study of Melanoma, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
- 14
- Study locations
NCT00623766 is a Phase 2 study of Melanoma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 99 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (86% lower). The trial reports 14 study locations across 11 states.
The verdict
NCT00623766, a Phase 2 study of Melanoma, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
- 14
- Study locations
Study Summary
To assess the response of melanoma with brain metastases to ipilimumab treatment while maintaining acceptable tolerability.
Conditions Studied
Interventions
- DRUG Ipilimumab
- DRUG Corticosteroid: Betamethasone
- DRUG Corticosteroid: Dexamethasone
- DRUG Corticosteroid: Fludrocortisone
- DRUG Corticosteroid: Hydrocortisone
Study Locations (14)
California
- City Of Hope - Duarte
- The Angeles Clinic & Research Institute - Los Angeles
Illinois
- Loyola University Medical Center - Maywood
- Oncology Specialists, S.C. - Park Ridge
New York
- Memorial Sloan Kettering Cancer Center - New York
- Local Institution - The Bronx
Arizona
- Mayo Clinic Arizona - Scottsdale
Connecticut
- Yale University School Of Medicine - New Haven
Indiana
- Indiana University Cancer Center - Indianapolis
Massachusetts
- Dana Farber Cancer Institute - Boston
New Hampshire
- Dartmouth Hitchcock Medical Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2008-07 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00623766
The ClinicalTrials.gov registry entry for NCT00623766 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (86% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 5 interventions - of which Ipilimumab is the first listed.
NCT00623766 reports 14 study locations spanning 11 distinct geographic areas - top geographies include California, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT00623766 about?
NCT00623766 is a clinical study titled "Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases". To assess the response of melanoma with brain metastases to ipilimumab treatment while maintaining acceptable tolerability.
What is the current status of trial NCT00623766?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2008-07. Estimated completion is 2012-10.
What conditions does trial NCT00623766 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT00623766?
The interventions under investigation include: Ipilimumab (DRUG), Corticosteroid: Betamethasone (DRUG), Corticosteroid: Dexamethasone (DRUG), Corticosteroid: Fludrocortisone (DRUG), Corticosteroid: Hydrocortisone (DRUG).
Who is sponsoring clinical trial NCT00623766?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00623766 being conducted?
This trial has 14 study locations across Arizona, California, Connecticut, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.